UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-39294 ASSERTIO HOLDINGS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 85-0598378 (STATE OR OTHER JURISDICTION O ...

Acquisition and Merger - The company completed the acquisition of Spectrum Pharmaceuticals on July 31, 2023, under a merger agreement, enhancing its portfolio in oncology products [116]. - Each share of Spectrum common stock was converted into the right to receive 0.1783 shares of the company's common stock and a contingent value right worth up to $0.20 per share based on future sales of ROLVEDON [117][119]. - The company anticipates that the results of Spectrum will be included in its consolidated financial statements from the effective date of the merger [119]. Financial Performance - Total revenues for the three months ended June 30, 2023, were $40.99 million, an increase of 2.4% from $35.13 million in the same period of 2022 [130]. - Total product sales, net, for the six months ended June 30, 2023, were $81.85 million, an increase of 15.4% from $70.98 million in the same period of 2022 [130]. - For the six months ended June 30, 2023, net income was $5.0 million, a decrease from $16.9 million for the same period in 2022 [166]. - Cash provided by operating activities was $41.3 million for the six months ended June 30, 2023, compared to $41.9 million in the same period in 2022 [165]. - Cash used in investing activities for the six months ended June 30, 2023, was $0.8 million, significantly lower than $16.5 million in the same period in 2022 [167]. - Cash used in financing activities for the six months ended June 30, 2023, was $35.3 million, compared to $9.9 million in the same period in 2022 [168]. Product Sales and Market Competition - INDOCIN net product sales increased by $5.2 million to $28.1 million for the three months ended June 30, 2023, compared to $22.8 million in 2022, driven by favorable net pricing despite a decrease in volume [132]. - Otrexup net product sales rose by $1.0 million to $3.6 million for the three months ended June 30, 2023, compared to $2.6 million in 2022, primarily due to higher volume [133]. - CAMBIA net product sales decreased by $4.4 million to $1.8 million for the three months ended June 30, 2023, compared to $6.2 million in 2022, mainly due to lower volume from generic competition [134]. - A generic version of INDOCIN Suppositories received FDA approval in August 2023, which may impact future sales and market competition [121][124]. - The company is focused on maintaining its market position despite the entry of generics and is developing strategies to enhance sales and marketing efforts [123][124]. Expenses and Financial Management - Selling, general, and administrative expenses increased by $6.2 million to $16.8 million for the three months ended June 30, 2023, primarily due to costs associated with the Spectrum Merger and higher marketing expenses [142]. - Research and development expenses were $0.5 million for both the three and six months ended June 30, 2023, representing costs associated with the proposed clinical trial for INDOCIN suppositories [141]. - Amortization of intangible assets decreased to $6.28 million for the three months ended June 30, 2023, from $7.97 million in 2022, primarily due to the full amortization of CAMBIA and Zipsor intangible assets [146]. - Other expense decreased from $2.36 million to $0.09 million for the three months ended June 30, 2023, primarily due to lower interest expenses [147]. - Debt-related expenses for the six months ended June 30, 2023, included an induced conversion expense of approximately $8.8 million related to a $30.0 million transaction [148]. - For the three and six months ended June 30, 2023, total interest expense decreased by $1.5 million and $2.7 million, respectively, compared to the same period in 2022, primarily due to lower interest incurred on outstanding debt [150]. Future Outlook and Strategy - The company expects potential future payments from the contingent value rights based on achieving specific sales targets for ROLVEDON, with $175 million in sales expected for 2024 and $225 million for 2025 [119]. - The company is committed to executing its business strategy, including product acquisitions and partnerships, to drive future growth [124]. - The company expects existing cash to be sufficient to fund operations and required payments under debt agreements for the next twelve months [159]. Tax and Financing Activities - The company recorded an income tax expense of $3.9 million for the three months ended June 30, 2023, representing an effective tax rate of 31.3% [152]. - The company completed a Convertible Note Exchange, exchanging $30.0 million principal amount of 2027 Convertible Notes for 6,990,000 shares of common stock and $10.5 million in cash [157]. - The company issued $70.0 million in aggregate principal amount of 2027 Convertible Notes, which are expected to reduce future cash interest expenses [156]. - The company has an ATM offering program with an aggregate offering price of up to $25.0 million, which was suspended following the issuance of the 2027 Convertible Notes [159]. Risks and Challenges - The company faces risks related to litigation, regulatory compliance, and market conditions that could affect its financial performance and operational results [126][127].

Assertio Holdings Inc. (NASDAQ:ASRT) Q2 2023 Earnings Call Transcript August 3, 2023 4:30 PM ET Company Participants Matt Kreps - Investor Relations Dan Peisert - President and CEO Paul Schwichtenberg - Senior Vice President and CFO Tom Riga - Outgoing CEO of Spectrum Pharmaceuticals Conference Call Participants Thomas Flaten - Lake Street Capital Markets Hamed Khorsand - BWS Financial Inc Jim Sidoti - SIDOTI & Company Scott Henry - Roth Capital Operator Good morning, and welcome to the Assertio Holdings In ...

Financial Data and Key Metrics Changes - Net product sales increased by 55% year-over-year, reaching $49.9 million in Q4 2022 compared to $32.2 million in Q4 2021 [6][17] - Adjusted EBITDA rose by 87% to $33.4 million in Q4 2022, with adjusted EBITDA margins improving to 66% from 53% in the prior year [6][20] - Adjusted EPS increased by 52% to $0.32 in Q4 2022, compared to $0.21 in the prior year [6][21] - Cash flow from operations surged nearly 6.5-fold to $26.7 million in Q4 2022 [6][23] Business Line Data and Key Metrics Changes - INDOCIN family net sales in Q4 2022 increased by $15.9 million year-over-year, primarily due to a shift to more profitable channels and normalization of customer inventory levels [18][39] - Combined net sales for OTREXUP and SYMPAZAN in Q4 2022 were $4.2 million, with SYMPAZAN outperforming internal expectations [6][18] - CAMBIA net sales remained flat at $7.3 million, while SPRIX net sales increased by $900,000 to $2.7 million [18][19] Market Data and Key Metrics Changes - The company noted a significant opportunity for INDOCIN due to updated ASGE guidelines recommending pre-procedure rectal NSAIDs for all patients, potentially expanding the market size [10][12] - The estimated annual use of INDOCIN in ERCP procedures is approximately 160,000, with the potential market being three times larger than the current usage [11][12] Company Strategy and Development Direction - The company aims to enhance its non-personal commercial platform, maintain INDOCIN, and pursue M&A opportunities to diversify its portfolio [7][16] - Assertio plans to invest in its commercial platform to improve ROI and demand growth [8] - The company is actively seeking acquisitions, with a goal to acquire an additional $32 million in gross profit by the end of 2023 [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, highlighting the successful acquisition of Sympazan and the positive impact of recent strategic actions [6][7] - The company anticipates product net sales for 2023 to be between $150 million and $160 million, despite the loss of exclusivity for Cambia [26][28] - Management acknowledged potential headwinds but indicated that these have been factored into the guidance provided [67] Other Important Information - The company generated $78.6 million in cash flow from operations for the full year 2022, a significant increase from the prior year [24] - Assertio's long-term debt balance was $66 million as of December 31, 2022, following a convertible debt refinancing that reduced cash interest rates [25][26] Q&A Session Summary Question: Update on 340B customers reordering - Management confirmed that reordering from 340B customers is north of 90% [32] Question: Direct distribution strategy update - Management stated that they are experiencing tremendous success in increasing direct distribution but kept specific metrics confidential for competitive reasons [34] Question: Impact of new ASGE guidelines on protocol design - Management indicated that the FDA recognizes the prior standard of care and does not anticipate significant impacts on the protocol design due to the new guidelines [36] Question: INDOCIN sales level in Q4 - Management clarified that INDOCIN sales in Q4 increased by $15.9 million year-over-year, with a $5 million inventory benefit [39][41] Question: Growth expectations for OTREXUP - Management expects OTREXUP to grow sequentially in 2023, having resolved previous supply issues [43] Question: R&D trial follow-up duration - Management noted that the follow-up for the trial would be 30 days, depending on enrollment speed [45] Question: Updates on orphan drug compound - Management refrained from providing specific timelines for the orphan drug compound, stating progress is slower than desired [47] Question: Tax rate and shares outstanding - Management projected a tax rate in the low double-digits and estimated shares outstanding to be in the mid-60s million range [49][50] Question: Transition speed for ASGE guideline change - Management expressed caution in predicting the growth opportunity from the guideline change but acknowledged it as a significant opportunity [53] Question: Inventory and manufacturing capacity - Management confirmed ample inventory and ongoing discussions with suppliers to accelerate purchase orders [55] Question: Pricing strategy - Management is comfortable with current pricing and does not anticipate supply shortages [57] Question: Upside for Sympazan - Management reported about $300,000 of upside for Sympazan in Q4, with strong early uptake [59][61] Question: SG&A expenses outlook - Management indicated a step-up in SG&A expenses for 2023 due to investments in Sympazan and clinical studies for INDOCIN [63] Question: Valuations in the current acquisition environment - Management noted that valuations are more reasonable now compared to previous years, with many attractive opportunities available [66] Question: Anticipated headwinds - Management stated that there are no new headwinds beyond those already included in the guidance [68]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-39294 ASSERTIO HOLDINGS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 85-0598378 (STATE OR OTHER JURISDICTION OF (I ...

Assertio Holdings, Inc. Q4 2022 Financial Results -ASSERTIO= About This Presentation Statements in this communication that are not statements of historical fact are forward-looking statements that reflect Assertio's current expectations, assumptions and estimates of future performance and economic conditions. These forward-looking statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as ...

Financial Reporting and Estimates - The preparation of financial statements requires management to make estimates and assumptions that could lead to material differences in actual results [180]. Drug Development Risks - The development of drug candidates is inherently difficult and uncertain, with significant risks of delays and failures in clinical trials [182]. - Regulatory approval processes are expensive and time-consuming, and delays could impair the ability to commercialize future products [189]. - The company relies on third-party organizations for clinical trials, which may affect the timing and success of obtaining regulatory approvals [185]. - Any significant delays in the governmental approval process could adversely impact the company's financial condition and results of operations [184]. - The company may need to perform additional clinical studies to support changes from approved products, which could further delay commercialization [191]. - The entry of generic competitors could significantly affect the market success of the company's products [193]. Market and Stock Performance - The trading price of the company's common stock has historically been volatile, influenced by various external factors [191]. - The company is currently in compliance with the Nasdaq's Bid Price Rule, which requires a minimum bid price of at least $1.00 per share [198]. - A failure to comply with the Bid Price Rule in the future could lead to delisting from the Nasdaq Capital Market, adversely affecting market liquidity and stock price [199]. - The company has previously required a grace period and implemented a one-for-four reverse stock split to maintain compliance with Nasdaq listing standards [198]. - The company is classified as a "smaller reporting company," which allows it to take advantage of reduced disclosure requirements, potentially making its stock less attractive to investors [200]. Corporate Governance and Shareholder Relations - The company may face significant costs and management distractions from potential proxy contests initiated by activist shareholders [201]. - The company is subject to risks related to unsolicited takeover attempts, which could disrupt business operations and financial results [202]. - The company may encounter difficulties in obtaining shareholder approval for significant corporate actions due to its retail investor base [199]. Legal and Financial Obligations - Legal and regulatory developments, including litigation and investigations, could impact the company's operations and financial performance [195]. - The company must generate sufficient cash flow to fund operations and meet its debt obligations [195]. - Variations in revenues from commercialization agreements and other contract revenues could affect financial metrics and projections [195].

Financial Data and Key Metrics Changes - Net product sales for Q3 2022 were $34.3 million, up from $26 million in the prior year quarter and down from $35.4 million in the previous quarter [20] - Adjusted EBITDA for Q3 2022 was $21.4 million, compared to $22.9 million last quarter and $15.8 million in the prior year quarter [24] - Net income for Q3 2022 was $4.2 million, compared to $7.8 million last quarter and $3.7 million in the prior year quarter [26] - Gross margin for Q3 2022 was 88.3%, with a slight adjustment due to a one-time returns accrual benefit [23] Business Line Data and Key Metrics Changes - INDOCIN family net sales increased by $7.3 million year-over-year, primarily due to higher net pricing [21] - Otrexup net sales for Q3 2022 were $3 million, up from $2.6 million in the prior quarter [21] - CAMBIA net sales decreased by $400,000 compared to the prior year quarter due to lower volume [22] Market Data and Key Metrics Changes - The company exited the Medicaid drug rebate program, which is expected to increase annual net revenue and profit by $6 million [12][14] - The acquisition of Sympazan is projected to add between $4 million to $4.5 million in annual adjusted EBITDA [15] Company Strategy and Development Direction - The company has pivoted towards growth after restructuring and improving profitability [7] - Key priorities include retaining employees, proving the efficacy of the new commercial model, reducing concentration in INDOCIN, and improving the balance sheet [8][10] - The company aims to diversify its business and has a robust M&A pipeline, with a goal of acquiring products that bring an additional $50 million in gross profit by 2024 [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the demand from the 340B hospital segment despite limited data [36] - The company is confident in its ability to grow and meet its goals, with a favorable M&A environment and capabilities to evaluate multiple transactions simultaneously [60] - The company expects to see a return to normal channel inventory levels, which should positively impact net product sales for INDOCIN [32] Other Important Information - The company raised its guidance for 2022, expecting product net sales to exceed $141 million and adjusted EBITDA to be greater than $86 million [31] - The company has successfully extended its debt maturity and reduced its cost of debt capital from 13% to 6.5% [7][10] Q&A Session Summary Question: Insights into demand from the 340B hospital segment - Management indicated limited insight due to data lag but remains optimistic about future demand [36] Question: Status of Otrexup sampling - Management confirmed that deliveries are on schedule and manufacturing timelines are being met [38] Question: Details on the pre-IND meeting with the FDA - Management stated that a single-arm trial is proposed, with specifics pending FDA feedback [40] Question: Impact of exiting the 340B program on revenues - Management clarified that exiting the program will save costs as previous sales were unprofitable [44] Question: Comfort level with returning to R&D - Management is actively recruiting for a Head of Medical to support clinical programs and is confident in the approach [47] Question: Long-term sales expectations for Otrexup - Management believes reaching a $4 million quarterly run rate is achievable [50] Question: Amortization expense for Sympazan - Management confirmed an amortization of $1.6 million per year over 10 years [52] Question: Expectations for Sympazan's growth - Management plans to integrate existing payer contracts and is optimistic about the asset's performance [66] Question: Overall growth expectations for 2023 - Management aims for growth in 2023 but did not provide specific guidance [68]

PART I — FINANCIAL INFORMATION [Item 1. Financial Statements (unaudited)](index=4&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) The unaudited financial statements show cash and equivalents increased to **$64.8 million**, with net income of **$21.1 million** for nine months, and operating cash flow at **$51.9 million** [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets slightly decreased to **$323.3 million**, while total liabilities reduced to **$188.4 million**, leading to an increase in shareholders' equity to **$134.9 million** Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | Sep 30, 2022 | Dec 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $64,826 | $36,810 | | Total current assets | $126,494 | $103,498 | | Intangible assets, net | $191,617 | $216,054 | | **Total assets** | **$323,344** | **$326,547** | | **Liabilities & Equity** | | | | Total current liabilities | $92,296 | $135,019 | | Total liabilities | $188,429 | $224,133 | | Total shareholders' equity | $134,915 | $102,414 | | **Total liabilities and shareholders' equity** | **$323,344** | **$326,547** | [Condensed Consolidated Statements of Comprehensive Income](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Income) Q3 2022 revenues rose to **$34.2 million** with **$4.2 million** net income, while nine-month revenues reached **$105.9 million**, shifting from a **$5.9 million** net loss to **$21.1 million** net income Statement of Comprehensive Income Summary (in thousands, except per share data) | Metric | Q3 2022 | Q3 2021 | Nine Months 2022 | Nine Months 2021 | | :--- | :--- | :--- | :--- | :--- | | Total revenues | $34,212 | $25,472 | $105,884 | $77,686 | | Income from operations | $6,434 | $5,934 | $28,783 | $1,443 | | Net income (loss) | $4,174 | $3,737 | $21,072 | $(5,887) | | Diluted net income (loss) per share | $0.08 | $0.08 | $0.42 | $(0.14) | [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Nine-month operating cash flow significantly increased to **$51.9 million**, with **$16.9 million** used in investing and **$7.0 million** in financing activities Cash Flow Summary for Nine Months Ended Sep 30 (in thousands) | Activity | 2022 | 2021 | | :--- | :--- | :--- | | Net cash provided by operating activities | $51,901 | $1,392 | | Net cash used in investing activities | $(16,889) | $0 | | Net cash (used in) provided by financing activities | $(6,996) | $36,548 | | **Net increase in cash and cash equivalents** | **$28,016** | **$37,940** | [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail the **$45.5 million** Otrexup acquisition, **$70 million** debt restructuring, ongoing legal proceedings, and the subsequent **Sympazan®** license acquisition - Acquired Otrexup from Antares Pharma for a total purchase price of **$45.5 million**, accounted for as an asset acquisition[24](index=24&type=chunk)[25](index=25&type=chunk) - Issued **$70.0 million** of 6.5% Convertible Senior Notes due 2027 and used the proceeds to repurchase outstanding 13% Senior Secured Notes due 2024[52](index=52&type=chunk)[58](index=58&type=chunk) - As of September 30, 2022, the company had a legal contingency accrual of approximately **$3.2 million** related to various lawsuits and investigations[73](index=73&type=chunk) - Subsequent to the quarter end, on October 27, 2022, the company acquired an exclusive license for Sympazan® from Aquestive Therapeutics for an upfront payment of **$9.0 million**[112](index=112&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=27&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes strong nine-month performance to increased **INDOCIN** sales and successful debt restructuring, believing current cash is sufficient for the next twelve months [Results of Operations](index=31&type=section&id=Results%20of%20Operations) Q3 2022 revenues grew **34%** to **$34.2 million**, driven by **INDOCIN** sales, while nine-month revenues increased **36%** to **$105.9 million**, with reduced SG&A expenses Net Product Sales Comparison (in millions) | Product | Q3 2022 | Q3 2021 | 9 Months 2022 | 9 Months 2021 | | :--- | :--- | :--- | :--- | :--- | | INDOCIN products | $21.9 | $14.5 | $66.1 | $42.2 | | CAMBIA | $5.8 | $5.0 | $17.5 | $17.6 | | Otrexup | $3.0 | $0.0 | $8.7 | $0.0 | | Zipsor | $0.3 | $2.0 | $2.7 | $6.8 | - The increase in total product sales was also supported by a decrease in gross-to-net deductions, attributed to a higher concentration of **INDOCIN** sales which have lower allowance levels[131](index=131&type=chunk) - SG&A expenses for the nine months ended Sep 30, 2022 decreased by **$8.3 million** compared to the same period in 2021, primarily because a **$11.3 million** loss contingency provision from 2021 did not repeat[137](index=137&type=chunk) [Liquidity and Capital Resources](index=35&type=section&id=Liquidity%20and%20Capital%20Resources) Liquidity improved with **$51.9 million** cash from operations, bolstered by issuing **$70.0 million** in convertible notes to repurchase **$59.0 million** of higher-interest debt - In August 2022, the company issued **$70.0 million** of 6.5% Convertible Senior Notes due 2027 and used the net proceeds to repurchase **$59.0 million** of its 13% Senior Secured Notes due 2024[150](index=150&type=chunk) - The company suspended its at-the-market (ATM) offering program after raising net proceeds of **$7.0 million**[151](index=151&type=chunk) - Cash provided by operating activities increased to **$51.9 million** for the nine months ended Sep 30, 2022, compared to **$1.4 million** in the prior year, driven by higher net income and favorable working capital changes[156](index=156&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=37&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This item is not applicable for the current reporting period - Not applicable[159](index=159&type=chunk) [Item 4. Controls and Procedures](index=37&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of September 30, 2022, with no significant changes in internal controls during Q3 2022 - Management, including the CEO and CFO, concluded that the company's disclosure controls and procedures were effective as of the end of the period[160](index=160&type=chunk) - No significant changes in internal controls over financial reporting were identified during the third quarter of 2022[162](index=162&type=chunk) PART II — OTHER INFORMATION [Item 1. Legal Proceedings](index=37&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in various legal proceedings, including **Glumetza** antitrust and extensive opioid-related litigation, as detailed in Note 13 - The company refers to Note 13 for a description of its material pending legal proceedings[163](index=163&type=chunk) [Item 1A. Risk Factors](index=37&type=section&id=Item%201A.%20Risk%20Factors) Significant risks include lack of patent protection for **INDOCIN**, generic competition for **Zipsor** and **Cambia**, potential Nasdaq delisting, and substantial debt obligations - The company faces competition for **INDOCIN** from a 503B compounder and could face generic competition at any time due to a lack of patent protection[165](index=165&type=chunk)[167](index=167&type=chunk) - Generic competition for **Zipsor** began in 2022, and generic competition for **Cambia** is expected to start in 2023, which will adversely affect revenues[165](index=165&type=chunk)[168](index=168&type=chunk) - The company's common stock may be delisted from Nasdaq if it fails to maintain the minimum **$1.00** bid price requirement, which would trigger a 'fundamental change' under its 2027 Convertible Notes[174](index=174&type=chunk)[177](index=177&type=chunk) - Significant indebtedness under the 2027 Convertible Notes poses a risk to the business, as failure to generate sufficient cash flow could lead to default and limit operational flexibility[179](index=179&type=chunk)[180](index=180&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=41&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) During Q3 2022, **12,477** shares were surrendered at an average price of **$2.27** to satisfy tax withholding for employee equity awards Issuer Purchases of Equity Securities (Q3 2022) | Period | Total Shares Purchased | Average Price Paid per Share | | :--- | :--- | :--- | | July 2022 | 6,190 | $2.65 | | August 2022 | 6,287 | $1.90 | | September 2022 | 0 | — | | **Total** | **12,477** | **$2.27** | - The shares purchased were withheld to pay employees' tax liability in connection with the vesting of equity awards and were not part of a publicly announced repurchase program[186](index=186&type=chunk)[188](index=188&type=chunk) [Item 3. Exhibits](index=43&type=section&id=Item%203.%20Exhibits) This section lists exhibits filed with Form 10-Q, including the Indenture for 6.50% Convertible Senior Notes, officer certifications, and XBRL data

Spectrum Pharmaceuticals, Inc. (SPPI) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Michael Grabow - SVP, Corporate Strategy and Operations Thomas J. Riga - President and CEO Francois J. Lebel - EVP and CMO Nora E. Brennan - EVP and CFO Conference Call Participants Unidentified Analyst - Jefferies Ed White - H.C. Wainwright Reni Benjamin - JMP Securities William Wood - B. Riley Securities Prakhar Agarwal - Cantor Fitzgerald Operator Good day and thank you for standing by. ...